IP Library Granted Patent US 11,891,362
Granted Patent B1
US 11,891,362 · App. 18/134,693 · Granted Feb 6, 2024

N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents

Inventors: Michelyne Haroun (Al-Ahsa, SA); Christophe Tratrat (Al-Ahsa, SA)
Assignee: KING FAISAL UNIVERSITY
C07D233/96A61P31/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,891,362
App. No.
18/134,693
Granted
Feb 6, 2024
Kind
B1
Abstract

The N2,N4-disubstituted pyrimidine-2,4-diamine derivative compounds are antibacterial agents having broad spectrum antibacterial activity. The present N2,N4-disubstituted pyrimidine-2,4-diamine compounds have antimicrobial activity against various susceptible and resistant gram-positive and gram-negative bacteria as well as drug resistant bacteria, such as MRSA and VRSA. The molecular target of these compounds was identified as DNA Gyrase B. Based on their pharmacological profiles, the present compounds may find important clinical applications for severe infectious diseases and tuberculosis.

Claims (21)

1. A compound having the formula I:

or a pharmaceutically acceptable salt, ester stereoisomer, or solvate thereof, wherein: each of X 1 , X 2 , X 3 , and X 4 is independently CH or nitrogen, wherein two of X 1 , X 2 , and X 3 , are nitrogen;

R 1 is a C 1 -C 6 alkyl; and

R 2 , R 3 and R 5 are each H, R 4 is a carboxylic acid, and R 6 is (cyclohexyl(methyl))aminomethyl.

2. The compound of claim 1 , wherein R 1 is methyl.

3. The compound of claim 1 , wherein X 1 and X 2 are nitrogen, X 3 is CH, and X 4 is CH or nitrogen.

4. The compound of claim 1 , wherein the compound is selected from the group consisting of:

4-((2-((3-acetamidophenyl)amino)pyrimidin-4-yl)amino)-3-((cyclohexyl(methyl)amino)methyl)benzoic acid (7),

and a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof.

5. A pharmaceutically acceptable composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

6. A compound having the formula I:

or a pharmaceutically acceptable salt, ester stereoisomer, or solvate thereof, wherein: X 1 and X 2 are nitrogen;

X 3 is CH;

X 4 is CH or nitrogen;

R 1 is methyl; and

each of R 2 , R 3 , and R 5 are hydrogen, R 4 is a carboxylic acid, and R 6 is a (cyclohexyl(methyl)amino)methyl.

7. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 6 and a pharmaceutically acceptable carrier.

8. A compound selected from the group consisting of:

4-((2-((3-acetamidophenyl)amino)pyrimidin-4-yl)amino)-3-((cyclohexyl(methyl)amino)methyl)benzoic acid (7),

and a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof.

9. A pharmaceutically acceptable composition comprising a therapeutically effective amount of the compound of claim 8 and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2023
From: HAROUN, MICHELYNE; TRATRAT, CHRISTOPHE
To: KING FAISAL UNIVERSITY
Reel/Frame 063343/0001 →